Abstract
Type 2 diabetes (T2D) is a metabolic disorder characterized by hyperglycaemia, insulin resistance at peripheral target tissues, and pancreatic β-cell dysfunction. It is a global health problem with epidemic proportions and a huge economic burden. The dipeptidyl peptidase (DPP-4) inhibitors are a new class of antihyperglycaemic agents that are developed for the treatment of T2D. Many clinical studies have suggested that DPP-4 inhibitors (gliptins) are safe from cardiovascular perspective, and may also possess cardioprotective effect. These are regulators of inflammation and metabolism, and also prevent the proteolytic breakdown. These reduce postprandial glucose with minimal risk of hypoglycaemia and gastrointestinal adverse effects. These increase biologically intact forms of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), both of which enhance glucose-induced insulin secretion from pancreatic β-cells. These medications become popular and are widely used worldwide for their efficacy, safety, weight neutrality, and tolerability. This article reviews basic studies of the DPP-4 inhibitors in briefly for the management of T2D.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
